Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 204.08M P/E - EPS this Y 47.20% Ern Qtrly Grth -
Income -89.91M Forward P/E -2.01 EPS next Y -1.50% 50D Avg Chg -8.00%
Sales 145.67M PEG 0.04 EPS past 5Y - 200D Avg Chg -46.00%
Dividend N/A Price/Book N/A EPS next 5Y -30.30% 52W High Chg -70.00%
Recommedations 1.90 Quick Ratio 3.31 Shares Outstanding 124.68M 52W Low Chg 24.00%
Insider Own 6.08% ROA -31.98% Shares Float 123.03M Beta 0.19
Inst Own 56.70% ROE - Shares Shorted/Prior 17.93M/18.26M Price 1.79
Gross Margin 89.19% Profit Margin -61.73% Avg. Volume 3,435,614 Target Price 4.36
Oper. Margin -65.72% Earnings Date Oct 31 Volume 2,225,002 Change -0.56%
About Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Karyopharm Therapeutics Inc. News
10/01/24 Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/05/24 Down -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics (KPTI) Looks Ripe for a Turnaround
09/03/24 Karyopharm to Participate at Upcoming Investor Conferences
09/02/24 Pipeline Moves: Investigator-led oncology cell therapy trial terminated
08/09/24 With 58% ownership, Karyopharm Therapeutics Inc. (NASDAQ:KPTI) boasts of strong institutional backing
08/07/24 Q2 2024 Karyopharm Therapeutics Inc Earnings Call
08/06/24 Karyopharm Therapeutics (KPTI) Q2 2024 Earnings Call Transcript
08/06/24 Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates
08/06/24 Karyopharm Therapeutics: Q2 Earnings Snapshot
08/06/24 Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
07/31/24 Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024
07/31/24 Earnings Preview: Assertio (ASRT) Q2 Earnings Expected to Decline
07/24/24 Karyopharm Therapeutics Inc. (KPTI): Is This One-Dollar Stock a Strong Buy Right Now?
07/15/24 Karyopharm Therapeutics Inc. (KPTI): Is This Penny Stock A Good Buy Right Now?
06/01/24 Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
05/29/24 Karyopharm to Participate at the Jefferies Global Healthcare Conference
05/23/24 The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom
05/10/24 Karyopharm Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
05/09/24 Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2024 Earnings Call Transcript
05/09/24 Karyopharm Therapeutics Inc (KPTI) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
KPTI Chatroom

User Image celebratelife Posted - 11 hours ago

$KPTI Destruction of the share price since Richard Paulson joined Karyofun, despite a life-saving cancer-curing medicine. It's time to fire Richard Paulson and break the spell. The stock will take off on that news.

User Image celebratelife Posted - 15 hours ago

$KPTI Chronic spending diarrhea culture, burning through shareholder funds, goes way back to horrible CEO Mike Kauffman days (great doctor and scientist but miserable CEO for Karyopharm and he never ran a company successfully before then - the only other company he ran as CEO went bankrupt). And horrible CEOs bring in people who are worse than themselves, so Mike hired two other Mikes: Mason and Mano. Richard Paulson is heaps worse than Kauffman as a CEO. After having spent hundreds of millions of dollars of shareholder money, the company deserves a competent, effective, turnaround CEO to cure this spending disease, build an ace team (in addition to Sohanya and Reshma who are superstars), streamline and right-size the operation, save a ton of money, and the stock will take off.

User Image celebratelife Posted - 2 days ago

$KPTI

User Image celebratelife Posted - 3 days ago

$KPTI

User Image mich1282 Posted - 3 days ago

$KPTI would be cool if some insiders purchased something.

User Image celebratelife Posted - 3 days ago

$KPTI Firing Richard Paulson seems to be the quickest path to prosperity for KPTI. The stock should be $5 today if it weren't for Paulson's mismanagement of stockholder assets.

User Image celebratelife Posted - 3 days ago

$KPTI Head of HR with all her fancy titles, Lisa DiPaolo, has been a disaster for Karyofun. The stock has gone down 85% since she joined us. So all her great ideas for bolstering employee morale, team work, etc., by burning a ton of cash funded by shareholders, and winning prizes for the best work environment, has been a total blunder because it failed short of achieving the goal for the ideal culture: productivity, driving bottom line, building value for the corporation. They’ve forgotten that because they’re too busy having fun and making sure they maximize their fun at our cost (it seems). Fire this lousy, wasteful HR head and Richard Paulson and Mike Mano and the stock will take off.

User Image AlertsAndNews Posted - 4 days ago

$KPTI Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country https://www.prnewswire.com/news-releases/antengene-announces-xpovio-selinexor-approved-for-its-third-indication-in-south-korea-bringing-fresh-hope-to-patients-with-mm-in-the-country-302279988.html Headline here after the AH close

User Image moneyrack Posted - 4 days ago

$KPTI unfortunately this is going towards the path of reverse split and that will result in note loss for long term shareholders

User Image ccrowder22 Posted - 4 days ago

$KPTI KPTI would be the perfect stock to run like DRUG… Tons of shorts would have to cover and it would skyrocket.

User Image celebratelife Posted - 4 days ago

$KPTI

User Image celebratelife Posted - 4 days ago

$KPTI

User Image seforim Posted - 5 days ago

$KPTI https://x.com/kinatsofrim/status/1846480668231881087

User Image Matooo Posted - 6 days ago

$STEC $KPTI

User Image Matooo Posted - 6 days ago

@topstockalerts $kpti is next up

User Image Matooo Posted - 6 days ago

$DRUG $KPTI

User Image Matooo Posted - 6 days ago

$DRUG $KPTI is next one up

User Image seforim Posted - 6 days ago

$KPTI Tomorrow https://x.com/kinatsofrim/status/1838981368446935177

User Image seforim Posted - 6 days ago

$KPTI https://x.com/kinatsofrim/status/1846247799983161468

User Image celebratelife Posted - 1 week ago

$KPTI

User Image seforim Posted - 1 week ago

$KPTI https://x.com/kinatsofrim/status/1845947012652441802

User Image ekpemofolo Posted - 1 week ago

Meanwhile the situation in biolandia: $KPTI holding nicely 80's. Goals are further ahead, but I wouldn't mind some breeze in the sails. $CTXR testing loyalty from retail. I suspect only those who trust their DD will remain after this bloodshed. $ARDX it is only a matter of "when" and "how much".

User Image DrMerpMcMerpleton Posted - 1 week ago

Brainless $KPTI

User Image DrMerpMcMerpleton Posted - 1 week ago

$KPTI nobody reads this crap

User Image celebratelife Posted - 1 week ago

$KPTI

User Image celebratelife Posted - 1 week ago

$KPTI

User Image celebratelife Posted - 1 week ago

$KPTI The linked post below about Paulson got over 110 views on Twitter, which is good given it's mostly hashtag visits. Mike Mano's head must be spinning since a) he seems too weak to understand there's nothing he can do about these critiques, and there are even laws that would make it backfire on them to try to quash shareholder criticisms b) his position and undeserved salary+bonus (in our opinion) are in danger. A new competent CEO would get rid of him c) he can't deny the fact that on his watch company value has been slaughtered d) he can't deny that competence and performance matters e) he may be wondering how to get another job after this lousy performance. https://x.com/karyowatch/status/1844493298809045172

User Image celebratelife Posted - 1 week ago

$KPTI

User Image seforim Posted - 1 week ago

$KPTI https://x.com/kinatsofrim/status/1844770261163196478

User Image DoctrBenway Posted - 1 week ago

@Egerton Dear Dr. Osler: As you're an oncologist dealing with AML, MDS, etc. I thought I'd get your opinions on Rytelo (imetelstat, $GERN) and Xpovio (selinexor, $KPTI). I've also followed if you want to take it to IMs. Best regards, Wm Welch. 😀

Analyst Ratings
HC Wainwright & Co. Buy Aug 7, 24
RBC Capital Outperform Aug 7, 24
Baird Outperform Aug 7, 24
HC Wainwright & Co. Buy Jun 28, 24
HC Wainwright & Co. Buy Jun 3, 24
HC Wainwright & Co. Buy May 9, 24
HC Wainwright & Co. Buy Mar 1, 24
Piper Sandler Overweight Nov 3, 23
RBC Capital Outperform Nov 3, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Paulson Richard A. President and CEO President and CEO Jan 04 Sell 0.82 4,114 3,373 783,465 01/08/24
Paulson Richard A. President and CEO President and CEO Dec 04 Sell 0.79 3,622 2,861 787,579 12/05/23
Paulson Richard A. President and CEO President and CEO Nov 06 Sell 0.9203 3,606 3,319 791,201 11/07/23
Paulson Richard A. President and CEO President and CEO Oct 04 Sell 1.27 3,589 4,558 794,807 10/05/23
BOHLIN GAREN G Director Director Sep 12 Buy 1.215 41,140 49,985 45,140 09/12/23
Paulson Richard A. President and CEO President and CEO Aug 07 Sell 1.72 3,722 6,402 802,018 08/08/23
Poulton Stuart EVP, Chief Developme.. EVP, Chief Development Officer Jul 28 Sell 1.70 2,845 4,836 156,286 08/01/23
Paulson Richard A. President and CEO President and CEO Jul 05 Sell 1.72 3,538 6,085 805,740 07/06/23
Rangwala Reshma EVP & Chief Medical.. EVP & Chief Medical Officer Apr 20 Sell 4.04 6,770 27,351 158,230 04/24/23
Paulson Richard A. President and CEO President and CEO Apr 04 Sell 3.97 3,497 13,883 816,619 04/05/23
Mason Michael EVP, CFO & Treasurer EVP, CFO & Treasurer Feb 28 Sell 3.03 11,205 33,951 245,361 03/02/23
Paulson Richard A. President and CEO President and CEO Feb 28 Sell 3.03 33,033 100,090 823,622 03/02/23
Paulson Richard A. President and CEO President and CEO Dec 05 Sell 5.17 3,490 18,043 612,527 12/06/22
Paulson Richard A. President and CEO President and CEO Nov 04 Sell 4.54 3,493 15,858 616,017 11/08/22
Paulson Richard A. President and CEO President and CEO Sep 08 Sell 5.24 3,479 18,230 622,998 09/09/22
Greene Barry E Director Director Aug 11 Option 1.485 7,576 11,250 13,606 08/15/22
Cheng Sohanya Roshan Chief Commercial Off.. Chief Commercial Officer Jun 13 Sell 5.27 1,551 8,174 89,949 06/14/22
PAKIANATHAN DEEPIKA Director Director Jun 08 Sell 6.23 538,784 3,356,624 16,673 06/10/22
Paulson Richard A. President and CEO President and CEO Jun 07 Sell 5.7602 2,542 14,642 630,906 06/08/22
Mason Michael EVP, CFO, Treasurer EVP, CFO, Treasurer Jun 03 Sell 6.05 601 3,636 138,509 06/06/22
Shacham Sharon Chief Scientific Off.. Chief Scientific Officer Feb 28 Sell 10.24 12,452 127,508 713,757 03/02/22
Kauffman Michael Director Director Feb 28 Sell 10.24 12,452 127,508 898,131 03/02/22
Kauffman Michael Director Director Feb 17 Sell 12.12 18,167 220,184 904,357 02/22/22
Shah Jatin EVP, Chief Medical O.. EVP, Chief Medical Officer Feb 07 Sell 9.862 1,704 16,805 130,756 02/09/22
Frenkel Ran EVP, Chief Dev. Offi.. EVP, Chief Dev. Officer Feb 07 Sell 9.862 1,991 19,635 104,632 02/09/22
Mason Michael EVP, CFO & Treasurer EVP, CFO & Treasurer Feb 07 Sell 9.862 3,947 38,925 53,308 02/09/22
Kauffman Michael Director Director Feb 07 Sell 9.86 13,471 132,824 913,445 02/09/22
Shacham Sharon Chief Scientific Off.. Chief Scientific Officer Feb 07 Sell 9.86 13,471 132,824 708,062 02/09/22
Shacham Sharon President & CSO President & CSO Feb 22 Sell 14.83 18,990 281,622 575,126 02/22/21
Shah Jatin EVP, Chief Medical O.. EVP, Chief Medical Officer Feb 17 Sell 15.52 1,748 27,129 48,127 02/17/21
Frenkel Ran EVP, Chief Dev. Offi.. EVP, Chief Dev. Officer Feb 17 Sell 15.52 2,046 31,754 39,338 02/17/21
Kauffman Michael Chief Executive Offi.. Chief Executive Officer Feb 17 Sell 15.52 13,243 205,531 764,147 02/17/21
Mirza Mansoor Raza Director Director Dec 22 Sell 18 5,000 90,000 12/22/20
Mirza Mansoor Raza Director Director Dec 22 Option 5.43 5,000 27,150 5,000 12/22/20
Lewis Tanya EVP,Chief Reg.&Quali.. EVP,Chief Reg.&Quality Officer Nov 04 Sell 15.58 226 3,521 539 11/04/20
Shah Jatin EVP, Chief Medical O.. EVP, Chief Medical Officer Nov 04 Sell 19.46 589 11,462 43,229 11/04/20
Primiano Christopher Brett EVP, CBO, GC & Secre.. EVP, CBO, GC & Secretary Oct 14 Option 9.8 39,271 384,856 5,370 10/14/20
Primiano Christopher Brett EVP, CBO, GC & Secre.. EVP, CBO, GC & Secretary Oct 14 Sell 17.03 39,271 668,785 4,649 10/14/20
Kauffman Michael Chief Executive Offi.. Chief Executive Officer Oct 14 Option 0.03 7,500 225 763,989 10/14/20
Kauffman Michael Chief Executive Offi.. Chief Executive Officer Oct 14 Sell 14.89 7,500 111,675 756,489 10/14/20
Shacham Sharon President & CSO President & CSO Oct 14 Option 0.03 7,500 225 763,989 10/14/20
Shacham Sharon President & CSO President & CSO Oct 14 Sell 14.89 7,500 111,675 756,489 10/14/20
Primiano Christopher Brett EVP, CBO, GC & Secre.. EVP, CBO, GC & Secretary Sep 10 Option 6.54 10,054 65,753 14,703 09/10/20
Primiano Christopher Brett EVP, CBO, GC & Secre.. EVP, CBO, GC & Secretary Sep 10 Sell 14.98 10,054 150,609 4,649 09/10/20